Preventing Recurrent VTE in Patients with Myeloproliferative Neoplasms

The lowest recurrence rates were observed in patients treated with cytoreduction and anticoagulation.

Reducing the risk for recurrent thrombosis is a major goal of therapy for patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Unfortunately, questions remain regarding optimal management, including the type and duration of the anticoagulant and the most effective cytoreductive agent.

Investigators conducted a systematic review in hopes of identifying the optimal management strategy, balancing safety and efficacy. Only 10 studies met inclusion criteria; none were randomized, controlled trials.

Among 1295 patients, the most prevalent MPN subtypes were ET (54%) and PV (37%). Antithrombotic strategies included low dose aspirin in 623 patients, vitamin K antag…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Preventing Recurrent VTE in Patients with Myeloproliferative Neoplasms

Topics

Reviewing Author